Predicting Detrusor Overactivity Using a Physician-based Scoring System

Overview

Journal Int Urogynecol J Pelvic Floor Dysfunct

Specialties Gynecology & Obstetrics
Urology

Date 2008 Apr 12

PMID 18404237

Citations 3

Authors

Maria Vella

Dudley Robinson

Linda Cardozo

Sushma Srikrishna

Rufus Cartwright

Affiliations

Soon will be listed here.

Abstract

Women with lower urinary tract symptoms (LUTS) commonly present to primary care. Management is often based on a symptomatic diagnosis alone although LUTS correlate with urodynamic diagnosis in 65% of cases. The aim of this study was to develop a scoring system to discriminate between the symptoms of stress urinary incontinence (SUI) and overactive bladder (OAB). Physicians completed a specially developed questionnaire for all women complaining of LUTS. Women then underwent videocystourethrography. A scoring system based on the likelihood of each symptom for DO was developed using odds ratios and 95% confidence intervals (CI). This scoring system was subsequently used to discriminate those women with OAB from those with SUI. One hundred seventy one women were recruited to the study. This scoring system had a sensitivity of 79%, a specificity of 78% and a positive predictive value of 73% to identify detrusor overactivity (DO) This new OAB scoring system may be used in primary care to help discriminate between USI and DO.

Citing Articles

A Novel Predictive Model of Detrusor Overactivity Based on Clinical Symptoms and Non-invasive Test Parameters in Female Patients with Lower Urinary Tract Symptoms.

Cheng Y, Li T, Wu X, Du G, Xu S Int Urogynecol J. 2024; 35(10):2065-2073.

PMID: 39297987 DOI: 10.1007/s00192-024-05896-z.

OAB score: a clinical model that predicts the probability of presenting overactive detrusor in the urodynamic study.

Cristian Arribillaga L, Ledesma M, Montedoro A, Pisano F, Bengio R Int Braz J Urol. 2017; 44(2):348-354.

PMID: 29211399 PMC: 6050563. DOI: 10.1590/S1677-5538.IBJU.2017.0213.

Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone.

Haylen B, Chiu T, Avery D, Zhou J, Law M Int Urogynecol J. 2014; 25(8):1115-20.

PMID: 24664215 DOI: 10.1007/s00192-014-2362-5.

References

Langer R, Lipshitz Y, Halperin R, Pansky M, Bukovsky I, Sherman D . Long-Term (10-15 years) follow-up after Burch colposuspension for urinary stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12(5):323-6; discussion 326-7. DOI: 10.1007/s001920170034. View

Blaivas J . The bladder is an unreliable witness. Neurourol Urodyn. 1996; 15(5):443-5. DOI: 10.1002/(SICI)1520-6777(1996)15:5<443::AID-NAU1>3.0.CO;2-F. View

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2):167-78. DOI: 10.1002/nau.10052. View

Digesu G, Khullar V, Cardozo L, Salvatore S . Overactive bladder symptoms: do we need urodynamics?. Neurourol Urodyn. 2003; 22(2):105-8. DOI: 10.1002/nau.10099. View

Jarvis G, Hall S, Stamp S, Millar D, Johnson A . An assessment of urodynamic examination in incontinent women. Br J Obstet Gynaecol. 1980; 87(10):893-6. DOI: 10.1111/j.1471-0528.1980.tb04443.x. View

Ahlberg J, Edlund C, Wikkelso C, Rosengren L, Fall M . Neurological signs are common in patients with urodynamically verified "idiopathic" bladder overactivity. Neurourol Urodyn. 2002; 21(1):65-70. DOI: 10.1002/nau.2094. View

Kelleher C, Cardozo L, Khullar V, Salvatore S . A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1998; 104(12):1374-9. DOI: 10.1111/j.1471-0528.1997.tb11006.x. View

Andersson K . The overactive bladder: pharmacologic basis of drug treatment. Urology. 1998; 50(6A Suppl):74-84; discussion 85-9. DOI: 10.1016/s0090-4295(97)00595-5. View

Kelleher C, Cardozo L, Khullar V, Salvatore S . A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997; 104(9):988-93. DOI: 10.1111/j.1471-0528.1997.tb12054.x. View

10.

Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A . Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002; 21(3):261-74. DOI: 10.1002/nau.10066. View

11.

Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A . How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9):760-6. DOI: 10.1046/j.1464-410x.2001.02228.x. View

12.

Duckett J, Vella M, Kavalakuntla G, Basu M . Tolerability and efficacy of duloxetine in a nontrial situation. BJOG. 2007; 114(5):543-7. DOI: 10.1111/j.1471-0528.2007.01288.x. View

13.

Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327-36. DOI: 10.1007/s00345-002-0301-4. View

14.

Graham C, Mallett V . Race as a predictor of urinary incontinence and pelvic organ prolapse. Am J Obstet Gynecol. 2001; 185(1):116-20. DOI: 10.1067/mob.2001.114914. View